Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas.
Francesco Bertoni(Ente Ospedaliero Cantonale), Franco Cavalli(Institute of Social and Preventive Medicine), Anna Sasso(Institute of Oncology Research), Sara Napoli(Institute of Oncology Research), Giancarlo Pruneri(University of Milan), Carlo V. Catapano(Institute of Oncology Research), Emanuele Zucca(Università della Svizzera italiana), Carlo Capella(University of Insubria), Vittoria Martin(University of Insubria), Silvia Uccella(University of Insubria), Maria Grazia Tibiletti(University of Insubria), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 0
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes
|The Journal of Immunology|2009|383